ADMA
Price
$15.67
Change
-$0.31 (-1.94%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
3.81B
42 days until earnings call
PPTDF
Price
$11.81
Change
+$0.81 (+7.36%)
Updated
Sep 16 closing price
Capitalization
1.45B
Interact to see
Advertisement

ADMA vs PPTDF

Header iconADMA vs PPTDF Comparison
Open Charts ADMA vs PPTDFBanner chart's image
ADMA Biologics
Price$15.67
Change-$0.31 (-1.94%)
Volume$34.5K
Capitalization3.81B
Peptidream
Price$11.81
Change+$0.81 (+7.36%)
Volume$1.3K
Capitalization1.45B
ADMA vs PPTDF Comparison Chart in %
Loading...
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PPTDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADMA vs. PPTDF commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Buy and PPTDF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (ADMA: $15.98 vs. PPTDF: $11.81)
Brand notoriety: ADMA and PPTDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 80% vs. PPTDF: 120%
Market capitalization -- ADMA: $3.81B vs. PPTDF: $1.45B
ADMA [@Biotechnology] is valued at $3.81B. PPTDF’s [@Biotechnology] market capitalization is $1.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whilePPTDF’s FA Score has 0 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • PPTDF’s FA Score: 0 green, 5 red.
According to our system of comparison, ADMA is a better buy in the long-term than PPTDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 5 TA indicator(s) are bullish while PPTDF’s TA Score has 3 bullish TA indicator(s).

  • ADMA’s TA Score: 5 bullish, 3 bearish.
  • PPTDF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ADMA is a better buy in the short-term than PPTDF.

Price Growth

ADMA (@Biotechnology) experienced а +1.85% price change this week, while PPTDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

ADMA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($3.81B) has a higher market cap than PPTDF($1.45B). ADMA has higher P/E ratio than PPTDF: ADMA (18.80) vs PPTDF (14.56). ADMA YTD gains are higher at: -6.822 vs. PPTDF (-33.838). ADMA has higher annual earnings (EBITDA): 163M vs. PPTDF (-3.66B). PPTDF has more cash in the bank: 33.3B vs. ADMA (90.3M). ADMA has less debt than PPTDF: ADMA (83.8M) vs PPTDF (18.3B). PPTDF has higher revenues than ADMA: PPTDF (19.1B) vs ADMA (474M).
ADMAPPTDFADMA / PPTDF
Capitalization3.81B1.45B263%
EBITDA163M-3.66B-4%
Gain YTD-6.822-33.83820%
P/E Ratio18.8014.56129%
Revenue474M19.1B2%
Total Cash90.3M33.3B0%
Total Debt83.8M18.3B0%
FUNDAMENTALS RATINGS
ADMA vs PPTDF: Fundamental Ratings
ADMA
PPTDF
OUTLOOK RATING
1..100
5931
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
33100
SMR RATING
1..100
1699
PRICE GROWTH RATING
1..100
8460
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADMA's Valuation (67) in the Biotechnology industry is in the same range as PPTDF (87) in the null industry. This means that ADMA’s stock grew similarly to PPTDF’s over the last 12 months.

ADMA's Profit vs Risk Rating (33) in the Biotechnology industry is significantly better than the same rating for PPTDF (100) in the null industry. This means that ADMA’s stock grew significantly faster than PPTDF’s over the last 12 months.

ADMA's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for PPTDF (99) in the null industry. This means that ADMA’s stock grew significantly faster than PPTDF’s over the last 12 months.

PPTDF's Price Growth Rating (60) in the null industry is in the same range as ADMA (84) in the Biotechnology industry. This means that PPTDF’s stock grew similarly to ADMA’s over the last 12 months.

PPTDF's P/E Growth Rating (100) in the null industry is in the same range as ADMA (100) in the Biotechnology industry. This means that PPTDF’s stock grew similarly to ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMAPPTDF
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
50%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
43%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
21%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
40%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
28%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
30%
Advances
ODDS (%)
Bullish Trend 28 days ago
88%
N/A
Declines
ODDS (%)
Bearish Trend 16 days ago
75%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
60%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PPTDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USAGX41.480.26
+0.63%
Victory Precious Metals and Minerals
CSMEX25.920.03
+0.12%
Carillon Scout Mid Cap A
HNCSX21.93N/A
N/A
Hartford International Growth R4
FAGOX211.46N/A
N/A
Fidelity Advisor Growth Opps M
TSLTX5.24-0.01
-0.19%
Transamerica Small Cap Value I3

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with IMTX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then IMTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
-0.31%
IMTX - ADMA
41%
Loosely correlated
+3.94%
CPRX - ADMA
40%
Loosely correlated
-1.35%
IRON - ADMA
39%
Loosely correlated
+1.08%
RYTM - ADMA
39%
Loosely correlated
-0.30%
SYRE - ADMA
39%
Loosely correlated
+4.77%
More

PPTDF and

Correlation & Price change

A.I.dvisor tells us that PPTDF and NVAX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PPTDF and NVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PPTDF
1D Price
Change %
PPTDF100%
N/A
NVAX - PPTDF
32%
Poorly correlated
-2.25%
HOTH - PPTDF
28%
Poorly correlated
+6.70%
ADMA - PPTDF
27%
Poorly correlated
-0.31%
VTYX - PPTDF
27%
Poorly correlated
-1.06%
AURA - PPTDF
22%
Poorly correlated
+0.97%
More